Commentary: Shared decision making for weight-lowering medications in China

IF 7.9 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Qingyi Jia, Sheyu Li
{"title":"Commentary: Shared decision making for weight-lowering medications in China","authors":"Qingyi Jia,&nbsp;Sheyu Li","doi":"10.1002/ctm2.70065","DOIUrl":null,"url":null,"abstract":"<p>One in eight adults are suffering from obesity and its complication in 2022 worldwide, with the US leading the top prevalence of 67% adults with overweight adults. Following the western countries, China is entering a pandemic of obesity with 34.8% of adults with overweight and 14.1% with obesity and the most rapid increase of the population.<span><sup>1, 2</sup></span> The increasing disease burden costs an estimating 2.15 million US dollars in China 2024.</p><p>NuSH agonists including GLP-1 receptor agonists, GLP-1/GIP dual agonists, GLP-1/glucagon receptor dual agonists, GLP-1/GIP/glucagon receptor triple agonists showed their efficacies in weight lowering.<span><sup>3</sup></span> Recent large systematic reviews demonstrated the weight-lowering effects of IH semaglutide in adults with overweight and obesity and trizepatide in people with type 2 diabetes.<span><sup>4, 5</sup></span> Both received or applied their approvals to the Chinese FDA. Retatrurtide, the triple agonist, in its phase 2 trials, indicated an almost certainly 10% body weight loss adding to lifestyle modification, the efficacy might surpass any other existing weight-lowering medications including Beinaglutide, Danuglipron, Dulaglutide, Exenatide, Loxenatide, Liraglutide, Orforglipron Mazdutide, Efinopegdutide, Surbodutide (Tirzepatide). All these medications represent competitive alternative therapies for bariatric surgery. The latest large trial for the first time demonstrated the cardiovascular benefits of semaglutide in adults with obesity but not diabetes.<span><sup>4</sup></span></p><p>The plentifulness of obesity treatment medications does not mean a one-pill-fit-all strategy in prescribing these medications. Generally, patients need these medications if they have difficulty in changing their lifestyles, reaching further achievements after all their efforts, or needing time-sensitive body weight loss.</p><p>For example, osteoarthritis is a common complication of obesity and dramatically raises the risk of sport-related injury especially when the joint bears great weight load during intensive exercise. In such cases, patients face difficulty in initiating lifestyle modification, especially the exercise. Anti-obesity medications help prevernt such sport-related injuries through a promising body weight loss that frees the weight load of the joint in the early phase of the obesity treatment. Gradually increasing exercise in parallel helps maintain the skeletal muscle mass and function as well as the basal metabolism rate.<span><sup>6</sup></span> For people reaching their weight-loss plateau, anti-obesity medications may help break the balancing and allow further uptitration of physical exercise. Anaesthesia can be dangerous for some candidates of bariatric surgery and very severe obesity with impaired ventilation. Anti-obesity medications in this case with intensive lifestyle modification may help lose 5–10% of body weight in a short period before bariatric surgery. Similar needs fit people with obesity and decompensated heart failure or other life-threatening diseases.</p><p>Both clinicians and patients are tangling in choosing these dazzling treatment options, bringing everything back to the very beginning again—why do people lose their body weight? The motivation of obesity treatment varies across individuals. A comprehensive interview bands clinicians and patients with common and clear purposes, which allows shared decision-making with rigorous evidence and good presentation.<span><sup>7</sup></span> Shared decision-making reflects the respect to the patients’ values and preferences and improves the compliance and the satisfaction of the healthcare receivers.<span><sup>8</sup></span></p><p>The SHARE approach is the most common framework for shared decision-making including five common steps: (1) seeking for participation, (2) helping the patient with the evidence treatment options; (3) assessing the patient's values and preferences, (4) reaching a decision; and (5) evaluating the decision (Figure 1). Anchoring the individualised motivation of obesity treatment, the discussion regarding the treatment options usually involves heavy input from the patients, who may figure out the pros and cons of the treatment in their daily life. The clinicians should inspire such consideration and encourage any questions. When choosing an individual medication, all domains of GRADE Evidence to Decision (EtD) framework are relevant including sections for formulating the question, making an assessment and drawing conclusions. The latest network meta-analysis (NMA) shows up a good example in sharing the evidence with the patients in a user-friendly.<span><sup>9</sup></span> A recent user test suggested the wide acceptability of our interactive decision aid based on our previous NMA in general practitioners. With these static and interactive digital tools, the SHARE approach fits almost all scenarios especially when the patients’ values and preferences are heterogeneous across individuals such as the choice of anti-obesity medications. In the framework, the clinicians disseminate the evidence to the patients through the decision aids and the patients express their situation, consideration and rationales in choosing the medications. During the discussion, clinicians may find concerns and gaps of the patients’ knowledge, attitude or behaviour in managing their body shape, allowing precision medical suggestions. The full frame thus improves the adherence and satisfaction of the patients.</p><p>Among challenges, weight regain is undoubtedly the most critical concern. The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial follow-up study, Semaglutide Treatment Effect in People with Obesity (STEP) program 1 (STEP1) showed two-thirds weight regain of the prior weight loss after one year of withdrawal.<span><sup>10</sup></span> To maintain long-term weight-lowering effects, most people achieving their ideal body shape have to use these medications in long term, with less than half of patients maintaining more than 5% weight loss after 52-week withdrawal.<span><sup>10</sup></span> And most of the weight loss regained in 12 years. The healthy diet and regular exercise as habits are thus critical for people trying to cease their drugs. Aiming to the physician should encourage the patient to develop a healthy diet and a regular exercise habit, while preparing the patient for the need for long-term using this medication.</p><p>In summary, with novel medications approving their weight-lowering effects, people with obesity expand their options when seeking to change the body shape. With heterogeneous values and preferences, motivation interview and shared decision-making are critical for modern management of obesity and related diseases.</p>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"14 11","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11502301/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70065","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

One in eight adults are suffering from obesity and its complication in 2022 worldwide, with the US leading the top prevalence of 67% adults with overweight adults. Following the western countries, China is entering a pandemic of obesity with 34.8% of adults with overweight and 14.1% with obesity and the most rapid increase of the population.1, 2 The increasing disease burden costs an estimating 2.15 million US dollars in China 2024.

NuSH agonists including GLP-1 receptor agonists, GLP-1/GIP dual agonists, GLP-1/glucagon receptor dual agonists, GLP-1/GIP/glucagon receptor triple agonists showed their efficacies in weight lowering.3 Recent large systematic reviews demonstrated the weight-lowering effects of IH semaglutide in adults with overweight and obesity and trizepatide in people with type 2 diabetes.4, 5 Both received or applied their approvals to the Chinese FDA. Retatrurtide, the triple agonist, in its phase 2 trials, indicated an almost certainly 10% body weight loss adding to lifestyle modification, the efficacy might surpass any other existing weight-lowering medications including Beinaglutide, Danuglipron, Dulaglutide, Exenatide, Loxenatide, Liraglutide, Orforglipron Mazdutide, Efinopegdutide, Surbodutide (Tirzepatide). All these medications represent competitive alternative therapies for bariatric surgery. The latest large trial for the first time demonstrated the cardiovascular benefits of semaglutide in adults with obesity but not diabetes.4

The plentifulness of obesity treatment medications does not mean a one-pill-fit-all strategy in prescribing these medications. Generally, patients need these medications if they have difficulty in changing their lifestyles, reaching further achievements after all their efforts, or needing time-sensitive body weight loss.

For example, osteoarthritis is a common complication of obesity and dramatically raises the risk of sport-related injury especially when the joint bears great weight load during intensive exercise. In such cases, patients face difficulty in initiating lifestyle modification, especially the exercise. Anti-obesity medications help prevernt such sport-related injuries through a promising body weight loss that frees the weight load of the joint in the early phase of the obesity treatment. Gradually increasing exercise in parallel helps maintain the skeletal muscle mass and function as well as the basal metabolism rate.6 For people reaching their weight-loss plateau, anti-obesity medications may help break the balancing and allow further uptitration of physical exercise. Anaesthesia can be dangerous for some candidates of bariatric surgery and very severe obesity with impaired ventilation. Anti-obesity medications in this case with intensive lifestyle modification may help lose 5–10% of body weight in a short period before bariatric surgery. Similar needs fit people with obesity and decompensated heart failure or other life-threatening diseases.

Both clinicians and patients are tangling in choosing these dazzling treatment options, bringing everything back to the very beginning again—why do people lose their body weight? The motivation of obesity treatment varies across individuals. A comprehensive interview bands clinicians and patients with common and clear purposes, which allows shared decision-making with rigorous evidence and good presentation.7 Shared decision-making reflects the respect to the patients’ values and preferences and improves the compliance and the satisfaction of the healthcare receivers.8

The SHARE approach is the most common framework for shared decision-making including five common steps: (1) seeking for participation, (2) helping the patient with the evidence treatment options; (3) assessing the patient's values and preferences, (4) reaching a decision; and (5) evaluating the decision (Figure 1). Anchoring the individualised motivation of obesity treatment, the discussion regarding the treatment options usually involves heavy input from the patients, who may figure out the pros and cons of the treatment in their daily life. The clinicians should inspire such consideration and encourage any questions. When choosing an individual medication, all domains of GRADE Evidence to Decision (EtD) framework are relevant including sections for formulating the question, making an assessment and drawing conclusions. The latest network meta-analysis (NMA) shows up a good example in sharing the evidence with the patients in a user-friendly.9 A recent user test suggested the wide acceptability of our interactive decision aid based on our previous NMA in general practitioners. With these static and interactive digital tools, the SHARE approach fits almost all scenarios especially when the patients’ values and preferences are heterogeneous across individuals such as the choice of anti-obesity medications. In the framework, the clinicians disseminate the evidence to the patients through the decision aids and the patients express their situation, consideration and rationales in choosing the medications. During the discussion, clinicians may find concerns and gaps of the patients’ knowledge, attitude or behaviour in managing their body shape, allowing precision medical suggestions. The full frame thus improves the adherence and satisfaction of the patients.

Among challenges, weight regain is undoubtedly the most critical concern. The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial follow-up study, Semaglutide Treatment Effect in People with Obesity (STEP) program 1 (STEP1) showed two-thirds weight regain of the prior weight loss after one year of withdrawal.10 To maintain long-term weight-lowering effects, most people achieving their ideal body shape have to use these medications in long term, with less than half of patients maintaining more than 5% weight loss after 52-week withdrawal.10 And most of the weight loss regained in 12 years. The healthy diet and regular exercise as habits are thus critical for people trying to cease their drugs. Aiming to the physician should encourage the patient to develop a healthy diet and a regular exercise habit, while preparing the patient for the need for long-term using this medication.

In summary, with novel medications approving their weight-lowering effects, people with obesity expand their options when seeking to change the body shape. With heterogeneous values and preferences, motivation interview and shared decision-making are critical for modern management of obesity and related diseases.

Abstract Image

评论:中国减重药物的共同决策。
在这一框架中,临床医生通过决策辅助工具向患者传播证据,患者则表达他们在选择药物时的情况、考虑因素和理由。在讨论过程中,临床医生可能会发现患者在体型管理的知识、态度或行为方面存在的问题和不足,从而提出精准的医疗建议。在各种挑战中,体重反弹无疑是最令人担忧的问题。塞马鲁肽对超重或肥胖症患者心血管结果的影响(SELECT)试验的后续研究、塞马鲁肽对肥胖症患者的治疗效果(STEP)计划 1(STEP1)显示,停药一年后,之前减掉的体重有三分之二反弹。为了保持长期的减重效果,大多数达到理想体型的人都必须长期使用这些药物,只有不到一半的患者在停药 52 周后体重减轻保持在 5%以上10 。因此,健康的饮食和规律的运动习惯对于试图停药的人来说至关重要。因此,医生应鼓励患者养成健康饮食和定期锻炼的习惯,同时让患者做好长期服药的准备。总之,随着新型药物的降体重效果得到认可,肥胖症患者在寻求改变体型时的选择范围也在扩大。面对不同的价值观和偏好,动机访谈和共同决策对于肥胖症及相关疾病的现代管理至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.90
自引率
1.90%
发文量
450
审稿时长
4 weeks
期刊介绍: Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信